FIELD: medicine.
SUBSTANCE: present group of inventions refers to medicine, namely to endocrinology, and concerns treating diabetes with super-fast insulin. That is ensured by administering the ultra-fast acting insulin preparation in a standard dose during meals, then determining the postprandial glucose level and if the postprandial level is > 140 mg/dl, an additional dose of super-fast insulin is administered, ranging from 25 % to 100 % of the initial dose.
EFFECT: such dosing regimen provides optimal control of glycemia level.
24 cl, 28 dwg, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| APPLICATION OF SUPERFAST-ACTING INSULIN | 2009 |
|
RU2519706C2 |
| TREATING DIABETES MELLITUS WITH LONG-ACTING INSULIN FORMULATIONS | 2014 |
|
RU2705797C2 |
| METHOD FOR PREVENTING GLP-1 SIDE EFFECTS | 2008 |
|
RU2474415C2 |
| ACTIVE SUBSTANCE DELIVERY | 2008 |
|
RU2467741C2 |
| PHARMACEUTICAL COMPOSITION | 2013 |
|
RU2670106C2 |
| METHOD AND APPARATUS FOR ASSISTING IN MANAGEMENT OF DRUG THERAPY OF DIABETES | 2019 |
|
RU2823201C2 |
| LIXISENATIDE AS ADD-ON THERAPY TO BASAL INSULIN IN TYPE 2 DIABETES | 2012 |
|
RU2606154C2 |
| METHODS OF DIACEREIN APPLICATION IN ADDITIONAL TREATMENT OF DIABETES | 2011 |
|
RU2563988C2 |
| LIXISENATIDE AND METFORMIN FOR TYPE 2 DIABETES TREATMENT | 2012 |
|
RU2623023C2 |
| INSULIN GLARGINE/LIXISENATIDE FIXED RATIO FORMULATION | 2014 |
|
RU2684398C2 |
